CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $36,246,865 | -23.5% | 798,565 | -5.4% | 0.01% | -20.0% |
| Q2 2023 | $47,411,297 | +38.0% | 844,519 | +11.2% | 0.01% | +42.9% |
| Q1 2023 | $34,365,256 | +18.0% | 759,789 | +6.1% | 0.01% | 0.0% |
| Q4 2022 | $29,121,945 | -48.4% | 716,407 | -17.0% | 0.01% | -50.0% |
| Q3 2022 | $56,412,000 | +1.1% | 863,223 | -6.0% | 0.01% | 0.0% |
| Q2 2022 | $55,787,000 | -8.8% | 918,017 | -5.8% | 0.01% | +27.3% |
| Q1 2022 | $61,191,000 | -70.0% | 974,831 | -63.8% | 0.01% | +83.3% |
| Q4 2021 | $203,932,000 | +46.6% | 2,691,094 | +116.5% | 0.01% | -68.4% |
| Q3 2021 | $139,145,000 | -38.8% | 1,243,144 | -11.4% | 0.02% | -40.6% |
| Q2 2021 | $227,176,000 | +21.6% | 1,403,273 | -8.5% | 0.03% | +10.3% |
| Q1 2021 | $186,892,000 | -36.9% | 1,533,789 | -20.7% | 0.03% | +20.8% |
| Q4 2020 | $296,072,000 | +482.8% | 1,933,720 | +218.4% | 0.02% | +140.0% |
| Q3 2020 | $50,800,000 | -18.0% | 607,361 | -28.0% | 0.01% | -33.3% |
| Q2 2020 | $61,955,000 | +146.6% | 843,042 | +42.3% | 0.02% | +87.5% |
| Q1 2020 | $25,124,000 | -47.1% | 592,397 | -24.0% | 0.01% | -38.5% |
| Q4 2019 | $47,476,000 | +121.8% | 779,501 | +49.3% | 0.01% | +62.5% |
| Q3 2019 | $21,408,000 | -75.3% | 522,270 | -71.7% | 0.01% | -27.3% |
| Q2 2019 | $86,789,000 | +230.5% | 1,842,702 | +150.7% | 0.01% | 0.0% |
| Q1 2019 | $26,257,000 | +39.8% | 735,058 | +11.8% | 0.01% | +57.1% |
| Q4 2018 | $18,787,000 | -59.9% | 657,615 | -37.7% | 0.01% | -56.2% |
| Q3 2018 | $46,800,000 | -18.9% | 1,055,260 | +7.4% | 0.02% | -20.0% |
| Q2 2018 | $57,734,000 | +76.7% | 982,538 | +37.4% | 0.02% | +66.7% |
| Q1 2018 | $32,682,000 | +853.9% | 714,990 | +390.1% | 0.01% | – |
| Q4 2017 | $3,426,000 | +147.0% | 145,901 | +88.0% | 0.00% | – |
| Q3 2017 | $1,387,000 | +333.4% | 77,623 | +288.1% | 0.00% | – |
| Q2 2017 | $320,000 | – | 20,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |